Safety and efficacy trial of the antiviral and anti-tumor activity of Velcade combined with (R)ICE in subjects with EBV and/or HHV-8 positive relapsed/ refractory AIDS-associated non-Hodgkin's lymphoma (AMC 053)

This is a pilot study of the drug Velcade, given alone and with a combination of chemotherapy drugs to treat your cancer. Velcade has been approved by the Food and Drug Administration (FDA) to treat other types of cancers and relapsed non-Hodgkin's lymphoma. This study is being done to find out if Velcade given alone and in combination with chemotherapy is an effective treatment for AIDS-associated lymphomas. The safety of the drug both alone and as part of a drug combination will be evaluated. There will be 18 participants in this study nationwide and about 2 participants at UCLA.

Inclusion Criteria:

• HIV positive men and women 18 years of age or older
• Non-Hodgkin's lymphoma that has not gone away despite treatment or has come back after treatment
• Ability to understand informed consent

Exclusion criteria:

• Current active uncontrolled infection
• Heart failure
• Pregnancy or breast feeding
• Active hepatitis B infection

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #09-09-080-01

If you think you might be interested in participating in this study, please contact the Recruitment coordinator at 310-557-9062 or email at CAREoutreach@mednet.ucla.edu

Return to Clinical Trials main page